EN DE

BTC Health Ltd (BTC) Fair Value & Analysis

Healthcare · AU · Market cap A$21.4M (≈ $15.5M) · ISIN AU000000BTC7

What is BTC Health Ltd really worth?

BH BTC Health Ltd BTC · AU
PriceA$0.0600
Fair ValueA$0.0255
Upside−57.5%
Quality36/100

Below-average quality, and trading another 135% above our fair value of A$0.0255.

As of Aug 30, 2026, the fair value of BTC Health Ltd is A$0.0255 per share against a price of A$0.0600, so the fair value sits 58% below the price. A model estimate blended from multiple valuation models, recalculated regularly.

Watch BTC Health Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free

Strengths

Highly profitable · 118.1% net margin
Ranks above peers (6/8)

Risks

!Mixed Growth (revenue 3y +30.4 %/yr)
!negative free cash flow
!Moderate moat 49/100
!Evidence only low, so the estimate is less certain
!Weak on past: 1 out of 100
Evidence: Low Range A$0.0255 – A$0.0255

Fair value as of: Aug 30, 2026

From 7 valuation models · updated 7 days ago

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

What matters now

  • The price sits above even our optimistic bull case (A$0.0255). The favourable scenario is already priced in.
  • Weak quality (36/100) and above fair value at the same time, the margin of safety is missing on both counts.
  • The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Price vs Fair Value (5 years)

A$0.0880 A$0.0150 Fair Value A$0.0255 Jun 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 30, 2026.

How to read this chart

60‑month range A$0.0150 – A$0.0880 · the A$0.0600 price screens above the A$0.0255 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 30, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

BTC Health Ltd (BTC) currently trades at A$0.0600, while our model-based Fair Value estimate is A$0.0255, implying the stock looks roughly 135.3% overvalued today. The Quality Score stands at 36/100 (below-average quality), in the Healthcare sector. Bull case: the Economic Profit group reads highest at a median of A$0.0200 per share, and 0 of the 5 models we run sit above the A$0.0600 price. Bear case: the Multiples group reads lowest at A$0.0100, and 5 of the 5 models stay below the price. Evidence for this calculation is low.

Trailing-twelve-month revenue stands at A$3.3K. Revenue declined 88.8% year over year. It earns a return on equity of −9.9%. The balance sheet holds a net cash position of A$1.5M. Fundamentals as of Aug 30, 2026

The share trades about 14% below its 52-week high and 20% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −56% fair-value upside, at −58%, BTC screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.

Model Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Residual Income best evidence A$0.0200 A$0.0200 A$0.0100 72
Gordon GGM A$0.0100 A$0.0200 A$0.0300 63
EV/EBIT A$0.0100 A$0.0100 A$0.0100 63
All 7 models by family
Earnings-Based
Graham-Dodd A$0.0100 59
Dividend Discount
Gordon GGM A$0.0100 A$0.0200 A$0.0300 63
DDM Multi-Stage A$0.0100 A$0.0200 A$0.0300 61
Multiples
EV/EBIT A$0.0100 A$0.0100 A$0.0100 63
Asset-Based
NCAV (Graham) A$0.0200 A$0.0200 A$0.0300 53
Economic Profit
Residual Income best evidence A$0.0200 A$0.0200 A$0.0100 72
Growth Earnings
Growth-Adj P/E A$0.0100 60

Widest divergence: Dividend Discount (A$0.0200) versus Multiples (A$0.0100). Highest evidence: Residual Income (72).

Notify me when BTC reaches fair value

Put BTC on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Free, no payment details. Unsubscribe anytime in one click.

Key figures & financial health

Dividend yield 3.8%
Net margin 118% FY2026
Return on equity 0.3% TTM
Return on assets (EBIT) −7.4% avg 5y
Operating margin −566% TTM
Revenue (TTM) A$29.4K TTM
More key figures
Growth
Revenue growth (YoY) +10.7% 3y avg +30.4%
EPS growth (YoY) +176%
Balance sheet & cash flow
Free cash flow −A$354K FY2026
Net cash A$1.5M FY2026

Figures from reported company fundamentals · as of Aug 30, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 36/100

Of which business quality 39 · Market factors (momentum, volatility) 49

Profitability 28
Margins and returns on capital today
Quality Growth 50
Are margins and returns improving?
Cashflow 33
Earnings quality: real cash, not paper profit
Fin. Strength 78
Balance sheet, leverage, solvency risk
Investment 33
Disciplined investing over empire-building
Low Volatility 75
Calm price path (market factor)
Momentum 39
Price trend over the last 3–12 months (market factor)
52W Momentum 36
Distance to the 52-week high (market factor)
Net Issuance 0
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.

About the company

BTC Health Limited is a Pooled Development Fund managed by LHC Capital Partners Pty Ltd specializing in seed/startup, early venture, mid venture, late venture, emerging growth and growth capital investments.

Full company description

BTC Health Limited is a Pooled Development Fund managed by LHC Capital Partners Pty Ltd specializing in seed/startup, early venture, mid venture, late venture, emerging growth and growth capital investments. It makes investments in the healthcare, acute pain management, neuro-spinal, cardiovascular, pharmaceutical, medical technologies, biotechnology sector with a focus on post-genomics, stem cell biology, convergence, silicon biology, and nanomedicine. Within post-genomics, it invests in functional genomics, transcriptomics, proteomics, structural genomics, glycomics, and pharmacogenomics. In the stem cell biology sector, the fund focuses on stem cell therapies. Within convergent technologies, it invests in biomaterials, bionics, biosensors, tissue engineering, microfluidics, and moletronics. In the silicon biology sector, the fund focuses on structure-based drug design, virtual screening, computational library design, and in silico ADME/tox. It invests in companies based in Australia & New Zealand. The fund invests in both listed and unlisted companies.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2022 – FY2026 · reported fiscal years

BTC Health Ltd reported revenue of A$29.4K in FY2026 versus A$95.0K in FY2022, a compound −25.4%/yr. Reported net income was A$34.7K in FY2026.

Growth Quality 54/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Latest Revenue (FY 2026)
A$29.4K
Latest YoY
+195.4%
Avg. revenue growth/yr (3Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+30.4%
Avg. revenue growth/yr (25Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
−14.7%
Value creation/yr (3Y) Earnings growth per share (CAGR 3 years) plus dividend yield: value created per share and year.
−65.4% · in AUD
Earnings growth per share plus dividend yield: the value created per share and year.
Earnings growth per share−69.2%
Dividend yield3.8%
Operating margin (EBIT) Operating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−1,717.1% (2021) → 118.0% (2026) · rising
Worst earnings drop99% (2026) · in AUD
⚠ Revenue per share shrinking 13.0%/yr over ~10Y (margin trend unclear) Structural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
Revenue −25.4%/yr
FY22 A$95.0K
FY23 A$13.3K
FY24 A$16.4K
FY25 A$10.0K
FY26 A$29.4K
Net income
FY22 −A$576K
FY23 −A$10.2M
FY24 A$1.1M
FY25 A$4.0M
FY26 A$34.7K

BTC screens 135% overvalued. Compare with Vertex Pharmaceuticals Incorporated →

Share or link this analysis
𝕏 Post WhatsApp LinkedIn Reddit
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "BTC Health Ltd Fair Value". https://www.fairvalue-calculator.com/stock/BTC.AU

Peer Group

Biotechnology · 627 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 36 · Below median
Fair Value upside −58% · Below median
Return on equity (TTM) 0% · Above median
Return on assets −2% · Above median
Net margin (TTM) 118% · Top 25%
Revenue growth 11% · Above median
Dividend yield (TTM) 3.8% · Top 25%

Valuation Multiples vs Biotechnology median · lower = cheaper

P/B 1.38× · Cheaper than median

Strength profile in five axes (Snowflake)

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE0 · sector 0
FUTURE54 · sector 0
PAST1 · sector 0
HEALTH0 · sector 98
DIVIDEND76 · sector 26

VALUE 0: the price sits above our fair-value range.

Insider activity: 40/100

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Aug 30, 2026).

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $547.55 $278.78 −49%
Regeneron Pharmaceuticals, Inc REGN $807.71 $594.40 −26%
argenx SE ARGX €877.60 €292.84 −67%
BeOne Medicines AG 688235 ¥271.00 ¥47.36 −83%
Samsung Biologics Co 207940 1,518,000 KRW 1,055,793 KRW −30%
Alnylam Pharmaceuticals, Inc ALNY $228.61 $51.70 −77%
Royalty Pharma plc RPRX $60.58 $24.22 −60%
Celltrion, Inc 068270 190,700 KRW 74,519 KRW −61%
BioNTech SE BNTX $103.76 $45.70 −56%
Incyte Corporation INCY $123.22 $115.79 −6%

Compare BTC Health Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screener Filter by region, size and sector Compare tool Two stocks side by side Extrinsic Value Calculator (Options) Splits an option premium into intrinsic and extrinsic (time) value. Peter Lynch Fair Value Formula & Calculator Apply Peter Lynch's fair value formula in seconds: fair P/E ≈ earnings growth (+ dividend) - free, with formula and example.

Frequently asked questions

Is BTC Health Ltd (BTC) overvalued or undervalued?
As of Aug 30, 2026, our model estimates a fair value of A$0.0255 versus a price of A$0.0600, about −58% upside (overvalued).
What is the fair value of BTC?
Our model-based fair value for BTC Health Ltd is A$0.0255 (as of Aug 30, 2026), built from audited fundamentals. The current price: A$0.0600.
What is the quality score of BTC?
BTC Health Ltd has a Quality Score of 36/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for BTC Health Ltd (BTC)?
Our model-based price target is the fair value of A$0.0255 (as of Aug 30, 2026) from 7 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the BTC Health Ltd stock forecast for 2026?
Our models put fair value at A$0.0255, about −58% upside versus a price of A$0.0600 (overvalued). The calculation is refreshed regularly with new filings.
What is the revenue of BTC Health Ltd (BTC)?
BTC Health Ltd reported trailing-twelve-month revenue of about A$3.3K (latest available figure, as of Aug 30, 2026).
What is the net profit margin of BTC?
The net profit margin of BTC Health Ltd is about 0.0%, meaning it keeps roughly 0.0% of revenue as net income. Based on the latest reported figures.
Does BTC Health Ltd pay a dividend?
BTC Health Ltd currently shows a dividend yield of about 3.79% relative to its recent price (as of Aug 30, 2026).
Free · no account needed

Watch BTC Health Ltd in the live analysis

One click puts BTC Health Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.